neilharner2, Author at Corcept Therapeutics

About neilharner2

This author has not written his bio yet.
But we are proud to say that neilharner2 contributed 7 entries already.

Entries by neilharner2

Miricorilant, a Selective Glucocorticoid Receptor Modulator, Reprograms Hepatic Gene Networks in Metabolic Dysfunction–Associated Steatohepatitis

Mayoral Monibas, et al. • 2025 • AASLD 2025

November 7, 2025

Phase 3 ROSELLA (GOG-3073, ENGOT-ov72) Trial of Relacorilant + Nab-paclitaxel vs Nab-paclitaxel in Platinum-resistant Ovarian Cancer: Primary Results and Outcomes in Older Patients

Olawaiye et al. • 2025 • IGCS

November 4, 2025

ROSELLA (GOG3073, ENGOTov72, APGOT-OV10): Relacorilant + Nab-Paclitaxel in the Subgroup of Patients With Platinum-Resistant Ovarian Cancer (PROC) Previously Exposed to a PARP Inhibitor

Lorusso et al. • 2025 • ESMO

October 19, 2025

BELLA: A Phase 2 Study of Relacorilant + Nab-Paclitaxel +/- Bevacizumab in Patients with Gynecologic Cancers

Lorusso et al. • 2025 • ESMO

October 18, 2025

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of Dazucorilant, A Selective Glucocorticoid Receptor Modulator, in Amyotrophic Lateral Sclerosis

Andrews, et al. • 2025 • NEALS 2025

October 9, 2025

Mifepristone, a Glucocorticoid Receptor Antagonist, Reduced HbA1c and Body Weight in Difficult-to-control Type 2 Diabetes with Hypercortisolism: The CATALYST Prevalence and Treatment Trial

DeFronzo, et al. • 2025 • EASD 2025

September 17, 2025

Difficult-to-Control Type 2 Diabetes and a Post-Dexamethasone Suppression Test Cortisol of 1.2–1.8 µg/dL: Findings From a Large Prospective Study

Buse, et al. • 2025 • EASD 2025

September 17, 2025